Target
Equilibrative nucleoside transporter 1
Description
Anti-Equilibrative nucleoside transporter 1 Antibody, Non-Fucosylated (BioBet-1292ZP) is a & monoclonal & IgG antibody against Equilibrative nucleoside transporter 1. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Equilibrative nucleoside transporter 1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
solute carrier family 29 (equilibrative nucleoside transporter), member 1
Background
This gene is a member of the equilibrative nucleoside transporter family. The gene encodes a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative (as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies. Multiple alternatively spliced variants, encoding the same protein, have been found for this gene.
Alternative Names
SLC29A1; solute carrier family 29 (equilibrative nucleoside transporter), member 1; ENT1; equilibrative nucleoside transporter 1; nucleoside transporter, es-type; solute carrier family 29 member 1; solute carrier family 29, member 1; equilibrative NBMPR-sensitive nucleoside transporter; solute carrier family 29 (nucleoside transporters), member 1; equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; equilibrative nitrobenzylmercaptopurine riboside (NBMPR)-sensitive nucleoside transporter
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with SLC29A1 include Hemolytic Disease Due To Fetomaternal Alloimmunization and Periampullary Adenocarcinoma
Related Pathways
Its related pathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics.
Function
Mediates the inflow and outflow of nucleosides across the cell membrane (balance transporter). It is sensitive to low concentrations of nitrophenylmercaptopurine nucleoside (NBMPR) and does not depend on sodium. It has a high affinity for adenosine. It is inhibited by dipyridamole and dilazep (anti-cancer chemotherapy drugs).
Post-translational modifications
Glycosylated.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-1292ZP
Description
The monoclonal antibody that recognize hENTl are useful as companion diagnostics for established cancer drugs such as nucleoside analogue drugs and/or drugs derived from nucleoside analogues. For example, the hENTl antibody are useful in conjunction with chemotherapy agents such as pyrimidine derivatives including, for example, cytarabine, gemcitabine, azacytidine, and derivatives thereof, and purine derivatives including, for example, fludarabine, cladribine, clofarabine and derivatives thereof.
Antibody Indication
Cancer
